Aquestive appoints Abigail L. Jenkins to Board of Directors

Aquestive Therapeutics, Inc.

Ms. Jenkins appointed as Class II director effective April 1, 2024, term through 2026 annual meeting.
Appointed to Nominating and Corporate Governance Committee; board size increased from 7 to 8 members.
Ms. Jenkins will receive 57,000 stock options under 2018 Equity Incentive Plan, vesting in 1/3 annual increments.
Board determined Ms. Jenkins is an independent director under Nasdaq rules.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Abigail L. Jenkins

Director

AQST · Aquestive Therapeutics, Inc.

Effective: 2024-04-01
Filed: April 1, 2024, 7:59 PM ET

On April 1,2024, Aquestive Therapeutics, Inc. (the “Company”) announced the appointment of Abigail L. Jenkins to the Board of Directors of the Company (the “Board”), effective April 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Abigail L. Jenkins was appointed as Director at Aquestive Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On April 1,2024, Aquestive Therapeutics, Inc. (the “Company”) announced the appointment of Abigail L. Jenkins to the Board of Directors of the Company (the “Board”), effective April 1, 2024.

View on SEC.gov

Aquestive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-013888

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.